These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16855080)

  • 1. A multiphasic absorption model best characterizes gastrointestinal absorption of divalproex sodium extended-release tablets.
    Dutta S; Reed RC
    J Clin Pharmacol; 2006 Aug; 46(8):952-7. PubMed ID: 16855080
    [No Abstract]   [Full Text] [Related]  

  • 2. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-a-day controlled-release dosage form of divalproex sodium I: formulation design and in vitro/in vivo investigations.
    Qiu Y; Cheskin HS; Engh KR; Poska RP
    J Pharm Sci; 2003 Jun; 92(6):1166-73. PubMed ID: 12761806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Every-12-hour administration of extended-release divalproex in patients with epilepsy: impact on plasma valproic acid concentrations.
    Reed RC; Dutta S; Cavanaugh JH; Locke C; Granneman GR
    Epilepsy Behav; 2006 Mar; 8(2):391-6. PubMed ID: 16473558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).
    Dutta S; Qiu Y; Samara E; Cao G; Granneman GR
    J Pharm Sci; 2005 Sep; 94(9):1949-56. PubMed ID: 16052544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC; Dutta S
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium.
    Dutta S; Reed RC
    Am J Health Syst Pharm; 2006 May; 63(10):904-6. PubMed ID: 16675645
    [No Abstract]   [Full Text] [Related]  

  • 9. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
    Dutta S; Reed RC
    Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium.
    Reed RC; Dutta S
    Am J Health Syst Pharm; 2004 Nov; 61(21):2284-9. PubMed ID: 15552636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations.
    Ahmad AM; Douglas Boudinot F; Barr WH; Reed RC; Garnett WR
    Biopharm Drug Dispos; 2005 Dec; 26(9):417-25. PubMed ID: 16216031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Valproic acid serum through concentrations estimated from 12 hours post-dose concentrations in patients treated with Depakine® Crono].
    Lampón N; Tutor JC
    Farm Hosp; 2013; 37(1):79-80. PubMed ID: 23461508
    [No Abstract]   [Full Text] [Related]  

  • 14. Bioequivalence in development of antiepileptic drugs.
    Sommerville KW
    Epilepsy Res; 2006 Jan; 68(1):82-5. PubMed ID: 16377144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of extended-release divalproex sodium tablets: morning versus evening administration.
    Dutta S; Reed RC; Cavanaugh JH
    Am J Health Syst Pharm; 2004 Nov; 61(21):2280-3. PubMed ID: 15552635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition of valproic acid in self-poisoned adults.
    Wilimowska J; Florek E; Piekoszewski W
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):22-6. PubMed ID: 16867166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
    Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing differences between valproic acid concentrate and divalproex sodium: a case report.
    Coffey G; Botts S; de Leon J
    J Clin Psychiatry; 2004 May; 65(5):724-5. PubMed ID: 15163266
    [No Abstract]   [Full Text] [Related]  

  • 19. Valproic acid delayed release (Stavzor).
    Med Lett Drugs Ther; 2009 Apr; 51(1309):27-8. PubMed ID: 19343008
    [No Abstract]   [Full Text] [Related]  

  • 20. Which oral valproic acid formulation is best for my patient?
    Knox JE; Freeland KN
    JAAPA; 2015 Jan; 28(1):21-3. PubMed ID: 25522023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.